Search
ChulaCov19 mRNA vaccine
go.drugbank.com/drugs/DB16445ExperimentalPre-clinical studies in mice and monkeys showed evidence that the vaccine facilitates an impressive generation of neutralizing antibodies[L30678]. … The next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January 2021.
Oxabolone cipionate
go.drugbank.com/drugs/DB13185ExperimentalOxabolone cipionate is the C17β cypionate ester and a prodrug of [DB01500]. A synthetic anabolic-androgenic (AAS) steroid, it is a derivative of 19-nortestosterone (nandrolone).
Categories: Alimentary Tract and Metabolism, Hormones, Hormone Substitutes, and Hormone AntagonistsMethyl salicylate 2-ethylbutyrate
go.drugbank.com/drugs/DB14130InvestigationalMixtures: Thera Derm Roll OnTestosterone enantate benzilic acid hydrazone
go.drugbank.com/drugs/DB13947ApprovedWithdrawnCategories: Testosterone and derivatives, Hormones, Hormone Substitutes, and Hormone AntagonistsGALE-301
go.drugbank.com/drugs/DB17262InvestigationalIt is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171] … GALE-301 is an investigational cancer immunotherapy.
Methoxy arachidonyl fluorophosphonate
go.drugbank.com/drugs/DB02465ExperimentalMethoxy arachidonyl fluorophosphonate, commonly referred as MAFP, is an irreversible active site-directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases. … It inhibits phospholipase A2 and fatty acid amide hydrolase with special potency, displaying IC50 values in the low-nanomolar range.
Ridaforolimus
go.drugbank.com/drugs/DB06233InvestigationalCategories: Antineoplastic and Immunomodulating AgentsTetrathiomolybdate
go.drugbank.com/drugs/DB05088InvestigationalTetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum.
Omburtamab
go.drugbank.com/drugs/DB15635Investigational[A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.